Credit Suisse’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-35
| Closed | – | – | 4060 |
|
|
2022
Q2 | $0 | Buy |
+35
| New | – | ﹤0.01% | 3975 |
|
|
2021
Q4 | – | Sell |
-30,179
| Closed | -$153K | – | 3630 |
|
|
2021
Q3 | $153K | Sell |
30,179
-15,544
| -34% | -$78.8K | ﹤0.01% | 3423 |
|
|
2021
Q2 | $289K | Buy |
45,723
+3,718
| +9% | +$23.5K | ﹤0.01% | 3294 |
|
|
2021
Q1 | $325K | Sell |
42,005
-66,171
| -61% | -$512K | ﹤0.01% | 3135 |
|
|
2020
Q4 | $709K | Sell |
108,176
-30,411
| -22% | -$199K | ﹤0.01% | 2791 |
|
|
2020
Q3 | $921K | Sell |
138,587
-48,874
| -26% | -$325K | ﹤0.01% | 2322 |
|
|
2020
Q2 | $1.56M | Buy |
187,461
+67,335
| +56% | +$561K | ﹤0.01% | 2029 |
|
|
2020
Q1 | $921K | Sell |
120,126
-5,635
| -4% | -$43.2K | ﹤0.01% | 2167 |
|
|
2019
Q4 | $1.04M | Buy |
125,761
+36,191
| +40% | +$300K | ﹤0.01% | 2471 |
|
|
2019
Q3 | $661K | Buy |
89,570
+53,478
| +148% | +$395K | ﹤0.01% | 2641 |
|
|
2019
Q2 | $404K | Sell |
36,092
-15,300
| -30% | -$171K | ﹤0.01% | 2901 |
|
|
2019
Q1 | $553K | Buy |
51,392
+18,901
| +58% | +$203K | ﹤0.01% | 2706 |
|
|
2018
Q4 | $490K | Sell |
32,491
-5,130
| -14% | -$77.4K | ﹤0.01% | 2757 |
|
|
2018
Q3 | $696K | Buy |
37,621
+321
| +0.9% | +$5.94K | ﹤0.01% | 2644 |
|
|
2018
Q2 | $853K | Sell |
37,300
-10,295
| -22% | -$235K | ﹤0.01% | 2686 |
|
|
2018
Q1 | $1.35M | Buy |
47,595
+14,549
| +44% | +$414K | ﹤0.01% | 2366 |
|
|
2017
Q4 | $697K | Buy |
33,046
+8,524
| +35% | +$180K | ﹤0.01% | 2765 |
|
|
2017
Q3 | $445K | Buy |
+24,522
| New | +$445K | ﹤0.01% | 3092 |
|
|
2017
Q1 | – | Sell |
-12,735
| Closed | -$139K | – | 3449 |
|
|
2016
Q4 | $139K | Sell |
12,735
-5,530
| -30% | -$60.4K | ﹤0.01% | 3532 |
|
|
2016
Q3 | $286K | Buy |
18,265
+4,388
| +32% | +$68.7K | ﹤0.01% | 3338 |
|
|
2016
Q2 | $142K | Buy |
+13,877
| New | +$142K | ﹤0.01% | 3680 |
|